-- 摩根士丹利周四发布的一份报告指出，甲骨文（ORCL）第三季度执行力和市场需求均有所提升，但GPU即服务（GPUaaS）业务的利润率仍存在不确定性。 报告称，过去两周甲骨文股价上涨超过20%，部分原因是人工智能计算需求数据持续强劲，以及市场对计算资本支出的预期有所改善。 报告指出：“如果投资者对人工智能相关的超大规模/新云资本支出以及客户集中度风险的预期进一步改善，股价可能还有进一步上涨的空间。” 报告补充道：“然而，要对该股持更乐观的态度，还需要进一步明确GPUaaS业务的毛利率状况和未来的融资路径（以及调整长期目标）。” 摩根士丹利维持对甲骨文的“持有”评级，但将目标价从213美元下调至207美元，理由是其风险回报状况均衡。
Price: $177.79, Change: $-9.71, Percent Change: -5.18%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.